Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab Post-HCT for High-Risk B-ALL
NCT04746209Phase 2Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Feb 2021
- Primary completion
- Feb 2024
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Medical College of Wisconsin. Started Feb 2021; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04746209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04746209.